Compare Becton Dickinson and Co (BDX) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Unilever plc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Unilever plc trades at $60.35 (market cap $129.73B). The key difference: Unilever plc is far larger — about 3.1× Becton Dickinson and Co's market cap, and Unilever plc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| BDX | UL | |
|---|---|---|
Market Cap | $41.51B | $129.73B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $74.59 |
52-Week Low | $135.49 | $55.05 |
Enterprise Value | $57.97B | $155.17B |
Dividend Yield | 2.79% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Unilever (UL) trades at $61.48, down 0.39% on the day, with a bullish technical signal driven by moving averages. The company reported $60.76B in 2024 revenue but missed Q1 and Q2 2025 EPS estimates. Recent news highlights strategic moves including a potential bid for Thorne and a $270M innovation center investment. The stock shows strong profitability with a 18.75% net margin and 53.32% ROE, though valuation ratios like P/E of 20.84 suggest fair pricing amid mixed analyst sentiment.
Outlook remains cautious with near-term earnings misses offset by long-term growth initiatives. Investment appeal hinges on successful integration of acquisitions and margin improvement. Key risks include competitive pressures and macroeconomic volatility. Analysts are divided with 24% buy ratings, reflecting balanced risk-reward at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
